Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 2
2001 1
2002 1
2003 5
2004 6
2005 8
2006 4
2007 4
2008 5
2009 6
2010 2
2011 2
2012 2
2013 4
2014 10
2015 6
2016 12
2017 2
2018 1
2019 5
2020 2
2021 1
2022 1
2023 5
2024 5
2025 3
2026 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

102 results

Results by year

Filters applied: . Clear all
Page 1
Management of Menopausal Symptoms: A Review.
Crandall CJ, Mehta JM, Manson JE. Crandall CJ, et al. JAMA. 2023 Feb 7;329(5):405-420. doi: 10.1001/jama.2022.24140. JAMA. 2023. PMID: 36749328 Review.
During the menopausal transition, approximately 50% to 75% of women have hot flashes, night sweats, or both (vasomotor symptoms) and more than 50% have genitourinary symptoms (genitourinary syndrome of menopause [GSM]). ...Hormonal therapy with estrogen is the first …
During the menopausal transition, approximately 50% to 75% of women have hot flashes, night sweats, or both (vasomotor symptom …
Menopause.
Nelson HD. Nelson HD. Lancet. 2008 Mar 1;371(9614):760-70. doi: 10.1016/S0140-6736(08)60346-3. Lancet. 2008. PMID: 18313505 Review.
Trials of therapies for vasomotor dysfunction have shown improvements with oestrogen, gabapentin, paroxetine, and clonidine, but little or no benefit with other agents; adverse effects of these treatments must also be considered. ...
Trials of therapies for vasomotor dysfunction have shown improvements with oestrogen, gabapentin, paroxetine, and clonidine, but litt …
Hormone Therapy and Other Treatments for Symptoms of Menopause.
Hill DA, Crider M, Hill SR. Hill DA, et al. Am Fam Physician. 2016 Dec 1;94(11):884-889. Am Fam Physician. 2016. PMID: 27929271 Free article.
Although estrogen is the most effective treatment for hot flashes, nonhormonal alternatives such as low-dose paroxetine, venlafaxine, and gabapentin are effective alternatives. ...One systematic review suggests modest improvement in hot flashes …
Although estrogen is the most effective treatment for hot flashes, nonhormonal alternatives such as low-dose paroxetine …
Pilot evaluation of paroxetine for treating hot flashes in men.
Loprinzi CL, Barton DL, Carpenter LA, Sloan JA, Novotny PJ, Gettman MT, Christensen BJ. Loprinzi CL, et al. Mayo Clin Proc. 2004 Oct;79(10):1247-51. doi: 10.4065/79.10.1247. Mayo Clin Proc. 2004. PMID: 15473404 Clinical Trial.
OBJECTIVE: To provide prospective information on the potential utility of paroxetine for treating hot flashes In men receiving androgen ablation therapy for prostate cancer. ...Overall, paroxetine was well tolerated by most patients. CONCLUSION: The re …
OBJECTIVE: To provide prospective information on the potential utility of paroxetine for treating hot flashes In men re …
Systematic review and network meta-analysis comparing the efficacy of fezolinetant with hormone and nonhormone therapies for treatment of vasomotor symptoms due to menopause.
Morga A, Ajmera M, Gao E, Patterson-Lomba O, Zhao A, Mancuso S, Siddiqui E, Kagan R. Morga A, et al. Menopause. 2024 Jan 1;31(1):68-76. doi: 10.1097/GME.0000000000002281. Epub 2023 Nov 27. Menopause. 2024. PMID: 38016166 Free PMC article.
Fezolinetant 45 mg reduced the frequency of moderate to severe VMS events per day significantly more than all non-HTs evaluated: paroxetine 7.5 mg (mean difference [95% credible interval {CrI}], 1.66 [0.63-2.71]), desvenlafaxine 50 to 200 mg (mean differences [95% CrI], 1. …
Fezolinetant 45 mg reduced the frequency of moderate to severe VMS events per day significantly more than all non-HTs evaluated: paroxeti …
Paroxetine treatment of mood disorders in women: premenstrual dysphoric disorder and hot flashes.
Yonkers KA. Yonkers KA. Psychopharmacol Bull. 2003 Spring;37 Suppl 1:135-47. Psychopharmacol Bull. 2003. PMID: 14566208 Review.
Evidence for the efficacy of antidepressants in the treatment of premenstrual dysphoric disorder (PMDD) and hot flashes associated with menopause and breast cancer has emerged. The clinical trials experience with paroxetine and the controlled-release (CR) for …
Evidence for the efficacy of antidepressants in the treatment of premenstrual dysphoric disorder (PMDD) and hot flashes associ …
Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial.
Stearns V, Beebe KL, Iyengar M, Dube E. Stearns V, et al. JAMA. 2003 Jun 4;289(21):2827-34. doi: 10.1001/jama.289.21.2827. JAMA. 2003. PMID: 12783913 Clinical Trial.
CONTEXT: Standard therapy for hot flashes has been hormone replacement with estradiol or progestational agents, but recent data suggest that antidepressants inhibiting serotonin reuptake may also be effective. ...PATIENTS: A total of 165 menopausal women aged 18 yea …
CONTEXT: Standard therapy for hot flashes has been hormone replacement with estradiol or progestational agents, but recent dat …
Paroxetine.
Shrestha P, Fariba KA, Abdijadid S. Shrestha P, et al. 2023 Jul 17. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan–. 2023 Jul 17. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan–. PMID: 30252278 Free Books & Documents.
Paroxetine is a selective serotonin reuptake inhibitor (SSRI). It is used to treat several diseases, including major depressive disorder, obsessive-compulsive disorder, social anxiety disorder, panic disorder, posttraumatic stress disorder, generalized anxiety disorder, an …
Paroxetine is a selective serotonin reuptake inhibitor (SSRI). It is used to treat several diseases, including major depressive disor …
Paroxetine (Brisdelle) for hot flashes.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2013 Oct 28;55(1428):85-6. Med Lett Drugs Ther. 2013. PMID: 24165707 No abstract available.
Role of paroxetine in the management of hot flashes in gynecological cancer survivors: Results of the first randomized single-center controlled trial.
Capriglione S, Plotti F, Montera R, Luvero D, Lopez S, Scaletta G, Aloisi A, Serra GB, Angioli R. Capriglione S, et al. Gynecol Oncol. 2016 Dec;143(3):584-588. doi: 10.1016/j.ygyno.2016.10.006. Epub 2016 Oct 15. Gynecol Oncol. 2016. PMID: 27751589 Clinical Trial.
Sleep and hot flashes were assessed at baseline, week 4 and week 16. RESULTS: Eighty women (91%) completed the study. ...CONCLUSIONS: This is the first randomized placebo-controlled study in gynecological cancer survivors that demonstrates that paroxetine sig …
Sleep and hot flashes were assessed at baseline, week 4 and week 16. RESULTS: Eighty women (91%) completed the study. ...CONCL …
102 results